ASNRT — Arab Society of Nephrology and Renal Transplantation

النسخة العربية من هذه الصفحة

Outcome of Patients Transplanted for C3 Glomerulopathy and Primary Immune Complex-Mediated Membranoproliferative Glomerulonephritis

In a Swiss multicenter cohort of patients transplanted for C3 glomerulopathy (C3G) and immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN), disease recurrence was the primary driver of graft loss, with rising proteinuria serving as an early biomarker of recurrence.

Background

Roughly half of patients with C3G and primary IC-MPGN reach kidney failure within 10 years of diagnosis, and because these patients are generally young, most are listed for kidney transplantation. Reported post-transplant outcomes have been heterogeneous and conflicting, largely derived from small retrospective single-center studies.

Study design

The authors analyzed patient and graft outcomes within the prospective nationwide Swiss Transplant Cohort Study, including 41 transplant recipients (10 with C3G and 31 with IC-MPGN), with a mean age at transplantation of 48 years. Living donors provided 53% of the organs, and mean follow-up was 4.7 years. Outcomes assessed included graft loss in relation to disease recurrence.

Key findings

Seven of 41 patients (4 C3G and 3 IC-MPGN) experienced disease recurrence at a mean of 1.2 years after transplantation. Following recurrence, 28% lost their graft compared with 11% of patients without recurrence, and disease recurrence was the primary cause of graft loss in all cases. New-onset or rapidly increasing proteinuria emerged as an early marker of recurrence, preceding a significant decline in eGFR. Overall, 14% of patients died during follow-up.

Clinical implications

The data suggest proteinuria may serve as an early, actionable biomarker of disease recurrence and should be incorporated into post-transplant monitoring and used as an endpoint in trials of novel complement modulators. Findings reinforce the need for careful surveillance and emerging complement-targeted therapies to improve graft survival in this population.

Category

Transplant

Source

Kidney International Reports

Read the original article

More from ASNRT News

Browse the latest news, society announcements, KDIGO guideline updates, and AJNT issue releases on the ASNRT newsroom.

All news · ASNRT home